Patent classifications
C07C311/14
Necrosis Inhibitors
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS
The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.
##STR00001##
NOVEL SULFONYLAMINOBENZAMIDE COMPOUNDS AS ANTHELMINTICS
The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.
##STR00001##
Histone deacetylase inhibitors and compositions and methods of use thereof
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##
Histone deacetylase inhibitors and compositions and methods of use thereof
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##
Dipeptidomimetics as inhibitors of human immunoproteasomes
The compounds of the present invention are represented by the following compounds having Formula I: ##STR00001##
where the substituents R.sup.1, R.sup.4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): ##STR00002##
where the substituents R.sup.1-R.sup.4, R.sup.x, R.sup.y, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
Dipeptidomimetics as inhibitors of human immunoproteasomes
The compounds of the present invention are represented by the following compounds having Formula I: ##STR00001##
where the substituents R.sup.1, R.sup.4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): ##STR00002##
where the substituents R.sup.1-R.sup.4, R.sup.x, R.sup.y, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
Modulators of Sestrin-GATOR2 interaction and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
Modulators of Sestrin-GATOR2 interaction and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.